Table 1.
Clinicopathological characteristics of 669 investigated patients
| Characteristics | Biopsy (n=179) | Prostatectomy (n=490) | All |
|---|---|---|---|
| Age (year), mean±s.d. | 70.0±8.3 | 67.0±7.1 | 67.8±7.6 |
| BMI (kg m−2), mean±s.d. | 24.1±2.9 | 24.6±3.1 | 24.5±3.1 |
| PSA level (ng ml−1), n (%) | |||
| <4 | 38 (21.2) | 62 (12.7) | 100 (15.0) |
| 4–10 | 37 (20.7) | 109 (22.2) | 146 (21.8) |
| >10 | 102 (57.0) | 319 (65.1) | 421 (62.9) |
| Unknown | 2 (1.1) | 0 (0) | 2 (0.3) |
| Major Gleason score, n (%) | |||
| 3 | 63 (35.2) | 219 (44.7) | 282 (42.2) |
| 4 | 79 (44.1) | 218 (44.5) | 279 (41.7) |
| 5 | 37 (20.7) | 53 (10.8) | 90 (13.4) |
| Sum of Gleason score, n (%) | |||
| 6 | 21 (11.7) | 91 (18.6) | 112 (16.7) |
| 3+4 | 41 (23.9) | 119 (24.3) | 160 (23.9) |
| 4+3 | 22 (22.9) | 68 (13.9) | 90 (13.4) |
| >7 | 95 (53.1) | 212 (43.3) | 307 (45.9) |
| Clinical tumor stage, n (%) | |||
| T0/T1 | 28 (15.6) | 112 (22.9) | 140 (20.9) |
| T2 | 65 (36.3) | 275 (56.1) | 340 (50.8) |
| T3 | 36 (20.1) | 81 (16.5) | 117 (17.5) |
| T4 | 28 (15.6) | 2 (0.4) | 30 (4.5) |
| Unknown | 22 (12.3) | 20 (4.1) | 42 (6.3) |
| Aberrant bone scan, n (%) | 54 (30.2) | 70 (14.3) | 124 (18.5) |
| Perineural invasiona, n (%) | NA | 241 (49.7) | NA |
| Lymphovascular invasiona, n (%) | NA | 41 (15.1) | NA |
| Biochemical recurrencea, n (%) | NA | 25 (7.5) | NA |
aMissing data in prostatectomy, 5 for perneural invasion; 218 for lymphovascular invasion; 157 for biochemical recurrence. s.d.: standard deviation; BMI: body mass index; PSA: prostate-specific antigen; NA: not available